64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Running, not enrolling · Phase 3

Conditions studied: Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy

In brief

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Key facts

Study ID

NCT06970847

Run by

Clarity Pharmaceuticals Ltd

People needed

220

Starts

2025-05-16

Expected to finish

2026-12-31

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Signed informed consent.
• Life expectancy ≥ 6 months as determined by the Investigator.
• Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
• Participant potentially eligible for salvage therapy with curative intent (i.e. aligns with the definition of loco-regional therapy as described in protocol Section 7.2).
• PSA level after definitive therapy:
• Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per AUA recommendation) or
• Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per ASTRO-Phoenix consensus definition).
• Participant willing to undergo biopsy of a 64Cu-SAR-bisPSMA PET-positive lesion for histological confirmation of PC, where this is safe and feasible.
• An Eastern Cooperative Oncology performance status of 0-2.

You may not qualify if…

• Participants who received investigational agent within 5 biological half-lives prior to Day 1.
• Participants administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
• Participants with known predominant small cell or neuroendocrine PC.
• Previous systemic therapy for PC (with the exception of neoadjuvant and adjuvant systemic therapy as part of the definitive therapy and/or salvage therapy with radiation).
• Ongoing treatment or treatment within 6 months of Day 1 with any systemic therapy (e.g. any investigational therapy, androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist, chemotherapy, immunotherapy or radiotherapy) for PC.
• Participants for whom there is an intent to initiate a prohibited medication(s)/treatment(s) (refer to Section 7.3) during the course of the participant's involvement in the study.
• Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
• Any serious medical condition or extenuating circumstance (including receiving the investigational product or not capable of having a PET scan) which the investigator feels may interfere with the procedures or evaluations of the study.

Where it is running

• UC Irvine — Irvine, California, United States
• Comprehensive Urology Medical Group — Los Angeles, California, United States
• Alarcon Urology Center — Montebello, California, United States
• Biogenix Molecular — Miami, Florida, United States
• Endeavor Health- Glenbrook Hospital — Glenview, Illinois, United States
• Indiana University Health-IU Simon Cancer Center — Indianapolis, Indiana, United States
• XCancer Research Network / LCMC Health EJGH — Metairie, Louisiana, United States
• M. Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota, United States
• St. Louis University — St Louis, Missouri, United States
• XCancer — Omaha, Nebraska, United States
• Albany Medical College — Albany, New York, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• Urology Associates, P.C. — Nashville, Tennessee, United States
• Urology Clinics of North Texas — Dallas, Texas, United States
• The Urology Place — San Antonio, Texas, United States
• Summit Urology — Murray, Utah, United States
• Intermountain Medical Center — Salt Lake City, Utah, United States
• St. Vincent's Hospital, Sydney — Darlinghurst, New South Wales, Australia
• Sydney Adventist Hospital — Wahroonga, New South Wales, Australia
• Westmead Private Hosptial — Westmead, New South Wales, Australia
• Royal Brisbane and Women's Hospital — Herston, Queensland, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.